Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes).

PURPOSE Children with acute lymphoblastic leukemia (ALL) and high hyperdiploidy (> 50 chromosomes) have improved outcome compared with other ALL patients. We sought to identify cytogenetic features that would predict differences in outcome within this low-risk subset of ALL patients. MATERIALS AND METHODS High-hyperdiploid ALL patients (N = 480) were enrolled between 1988 and 1995 on Children's Cancer Group (CCG) trials. Karyotypes were determined by conventional banding. Treatment outcome was analyzed by life-table methods. RESULTS Patients with 54 to 58 chromosomes had better outcome than patients with 51 to 53 or 59 to 68 chromosomes (P = .0002). Patients with a trisomy of chromosome 10 (P<.0001), chromosome 17 (P = .0002), or chromosome 18 (P = .004) had significantly improved outcome compared with their counterparts who lacked the given trisomy. Patients with a trisomy of chromosome 5 had worse outcome than patients lacking this trisomy (P = .02). Patients with trisomies of both chromosomes 10 and 17 had better outcome than those with a trisomy of chromosome 10 (P = .09), a trisomy of chromosome 17 (P =.01), or neither trisomy (P<.0001). Multivariate analysis indicated that trisomy of chromosome 10 (P = .001) was the most significant prognostic factor for high-hyperdiploid patients, yet trisomy of chromosome 17 (P =.02) or chromosome 5 (P = .01) and modal chromosome number (P = .02) also had significant multivariate effects. CONCLUSION Trisomy of chromosomes 10 and 17 as well as modal chromosome number 54 to 58 identify subgroups of patients with high-hyperdiploid ALL who have a better outcome than high-hyperdiploid patients who lack these cytogenetic features. Trisomy of chromosome 5 confers poorer outcome among high-hyperdiploid patients.

[1]  S. Raimondi,et al.  Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. , 1999, Blood.

[2]  N. Heerema,et al.  Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Y. Ravindranath,et al.  Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  F. Behm,et al.  Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. , 1998, Blood.

[5]  H. Sather,et al.  Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. , 1998, The New England journal of medicine.

[6]  H. Sather,et al.  Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Adams,et al.  TEL-AML1 Fusion Transcript in Relapsed Childhood Acute Lymphoblastic Leukemia , 1998 .

[8]  H. Sather,et al.  Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T‐cell phenotype or other poor prognostic features , 1998, Cancer.

[9]  J. Downing,et al.  12p Abnormalities and the TEL Gene (ETV6) in Childhood Acute Lymphoblastic Leukemia , 1997 .

[10]  H. Sather,et al.  Early response to therapy and outcome in childhood acute lymphoblastic leukemia , 1997, Cancer.

[11]  S. Richards,et al.  Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X , 1997, British journal of haematology.

[12]  H. Sather,et al.  Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. , 1996, Leukemia & lymphoma.

[13]  F. Behm,et al.  Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. , 1996, Leukemia.

[14]  R. Pieters,et al.  Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. , 1995, Blood.

[15]  C. C. Bailey,et al.  Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X , 1995, The Lancet.

[16]  M. Relling,et al.  Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. , 1994, The Journal of clinical investigation.

[17]  S. Raimondi.  Current Status of Cytogenetic Research in Childhood Acute Lymphoblastic Leukemia , 1993 .

[18]  H. Sather,et al.  Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Look,et al.  Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1992, Blood.

[20]  A. Look,et al.  Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. , 1992, Blood.

[21]  F. Behm,et al.  Hyperdiploid (47-50) acute lymphoblastic leukemia in children. , 1992, Blood.

[22]  L. Frankel,et al.  Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Peto,et al.  Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (Report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood) , 1991, British journal of haematology.

[24]  M. Borowitz,et al.  Favorable prognosis associated with hyperdiploidy in children with acute lymphocytic leukemia correlates with extra chromosome 6. A pediatric oncology group study , 1990, Cancer.

[25]  C. Bloomfield,et al.  Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. , 1989, Cancer genetics and cytogenetics.

[26]  S. Richards,et al.  Chromosomes and other prognostic factors in acute lymphoblastic leukaemia: a long‐term follow‐up , 1989, British journal of haematology.

[27]  B. Koller,et al.  Biphenotypic leukemic lymphocyte precursors in CD2+CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues. , 1989, Blood.

[28]  C. Song,et al.  Heterogeneity of cultured leukemic lymphoid progenitor cells from B cell precursor acute lymphoblastic leukemia (ALL) patients. , 1987, The Journal of clinical investigation.

[29]  R. Gelber,et al.  Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. , 1986, The New England journal of medicine.

[30]  N. Heerema,et al.  Karyotypic and clinical findings in a consecutive series of children with acute lymphocytic leukemia. , 1985, Cancer genetics and cytogenetics.

[31]  C. Pui,et al.  Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia. , 1985, Blood.

[32]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[33]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[34]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[35]  F. Behm,et al.  Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis. , 1999, Blood.

[36]  J. Downing,et al.  Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup , 1999, Leukemia.

[37]  C. Pui,et al.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  G. Henze,et al.  Results and significance of six randomized trials in four consecutive ALL-BFM studies. , 1990, Haematology and blood transfusion.

[39]  J. Whang‐Peng.  Clinical significance of chromosomal abnormalities in acute lymphoblastic leukemia , 1981 .

[40]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .

[41]  D. Cox.  Regression Models and Life-Tables , 1972 .